Rigel Pharmaceuticals (RIGL) Other financing activities (2014 - 2026)

Rigel Pharmaceuticals' Other financing activities history runs 13 years deep, the most recent figure standing at $321000.0 for Q1 2026.

• In Q1 2026, Other financing activities fell 33.68% year-over-year to $321000.0; the TTM figure through Mar 2026 stood at $7.9 million (up 236.5% YoY), while the FY2025 annual figure was $8.1 million, up 312.47% from the prior year.
• Other financing activities for Q1 2026 stood at $321000.0, down from $2.9 million in the prior quarter.
• The five-year high for Other financing activities was $4.3 million in Q3 2025, with the low at $1000.0 in Q1 2023.
• The 5-year median for Other financing activities is $485000.0 (2023), against an average of $847437.5.
• The sharpest annual moves came in 2023 and 2024: Other financing activities slumped 99.89% in 2023, then soared 8800.0% in 2024.
• Rigel Pharmaceuticals' Other financing activities stood at $585000.0 in 2022, then retreated by 16.92% to $486000.0 in 2023, then jumped by 201.44% to $1.5 million in 2024, then surged by 99.86% to $2.9 million in 2025, then slumped by 89.04% to $321000.0 in 2026.
• Business Quant data shows RIGL's Other financing activities at $321000.0 in Q1 2026, $2.9 million in Q4 2025, and $4.3 million in Q3 2025.